These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25997310)

  • 1. Relief of photoallergy: atorvastatin replacing simvastatin.
    Sommer M; Trautmann A; Stoevesandt J
    J Investig Allergol Clin Immunol; 2015; 25(2):138-40. PubMed ID: 25997310
    [No Abstract]   [Full Text] [Related]  

  • 2. Fixed drug eruption due to atorvastatin.
    Huertas AJ; Ramírez-Hernández M; Mérida-Fernández C; Chica-Marchal A; Pajarón-Fernández M J ; Carreño-Rojo A
    J Investig Allergol Clin Immunol; 2015; 25(2):155-6. PubMed ID: 25997318
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk factors for rhabdomyolysis with simvastatin and atorvastatin.
    Golomb B; Evans M
    Drug Saf; 2006; 29(12):1191; author reply 1191-2. PubMed ID: 17147465
    [No Abstract]   [Full Text] [Related]  

  • 4. [Statins after drug discontinuation are usually well tolerated].
    Steurer J
    Praxis (Bern 1994); 2013 Jun; 102(13):813. PubMed ID: 23773943
    [No Abstract]   [Full Text] [Related]  

  • 5. Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones.
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2004 Jun; 93(11):1417-8, A9. PubMed ID: 15165929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paradoxical decrease in serum high-density lipoprotein cholesterol and lipid-lowering drugs.
    Crook MA
    Ann Clin Biochem; 2011 Jan; 48(Pt 1):3-4. PubMed ID: 21273636
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
    Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.
    S Afr Med J; 2002 Aug; 92(8):596-7. PubMed ID: 12244613
    [No Abstract]   [Full Text] [Related]  

  • 9. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
    Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
    Waters DD; Ho JE; Boekholdt SM; DeMicco DA; Kastelein JJ; Messig M; Breazna A; Pedersen TR
    J Am Coll Cardiol; 2013 Jan; 61(2):148-52. PubMed ID: 23219296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
    McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
    Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of high-dose atorvastatin compared with usual-dose simvastatin: less than IDEAL?
    Kaul P
    Eur Heart J; 2007 Jun; 28(12):1405-6. PubMed ID: 17553925
    [No Abstract]   [Full Text] [Related]  

  • 13. Statin wars: efficacy vs. cost.
    Wierzbicki AS
    Int J Clin Pract; 2011 Feb; 65(2):108-11. PubMed ID: 21235691
    [No Abstract]   [Full Text] [Related]  

  • 14. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
    Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
    Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
    Ramachandran S; Saraf S; Shetty C; Capps N; Bailey C
    Ann Clin Biochem; 2011 Jan; 48(Pt 1):75-8. PubMed ID: 21115572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ezetimib plus statin combination. A strong duo].
    MMW Fortschr Med; 2002 Nov; 144(48):53. PubMed ID: 12532547
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
    Swindle JP; Potash J; Kulakodlu M; Kuznik A; Buikema A
    Am J Geriatr Pharmacother; 2011 Dec; 9(6):471-82. PubMed ID: 22019005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland.
    Helin-Salmivaara A; Korhonen MJ; Alanen T; Huupponen R
    J Clin Pharm Ther; 2012 Feb; 37(1):58-64. PubMed ID: 21410736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
    Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
    Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of high-dose atorvastatin therapy.
    Waters DD
    Am J Cardiol; 2005 Sep; 96(5A):69F-75F. PubMed ID: 16126026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.